Literature DB >> 11352666

Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells.

I Kalajzic1, M L Stover, P Liu, Z Kalajzic, D W Rowe, A C Lichtler.   

Abstract

Marrow stromal cells (MSC) and neonatal calvarial cells have the potential to differentiate and express markers of mature osteoblasts. Furthermore, MSCs can generate multiple differentiated connective tissue phenotypes. These properties and their ability to be expanded ex vivo make them good models for ex vivo gene therapy. In this study we examined the ability of vesicular stomatitis virus (VSV-G) pseudotyped retroviral vectors to transduce osteoprogenitor cells derived from bone marrow and from neonatal calvaria. Retrovectors encoding either beta-galactosidase or green fluorescent protein (eGFP) were used for transduction of primary murine marrow stromal and primary neonatal calvarial cell cultures. High infection efficiency was demonstrated by fluorescence-activated cell analysis when GFP was used as a marker or by estimating the number of beta-galactosidase-positive cells. Expression of markers of differentiated bone cells, including Col1a1, bone sialoprotein, and osteocalcin mRNA and alkaline phosphatase activity was not impaired by retroviral transduction. Our data suggest that VSV-G pseudotypes retroviral vectors are suitable for introducing genes into osteoprogenitor cells without affecting osteoprogenitor lineage progression. Copyright 2001 Academic Press.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2001        PMID: 11352666     DOI: 10.1006/viro.2001.0903

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

Review 1.  A strategy for identifying osteoporosis risk genes.

Authors:  David Rowe; Alexander Lichtler
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

2.  Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly.

Authors:  Kathrin Hueging; Mandy Doepke; Gabrielle Vieyres; Dorothea Bankwitz; Anne Frentzen; Juliane Doerrbecker; Frauke Gumz; Sibylle Haid; Benno Wölk; Lars Kaderali; Thomas Pietschmann
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

3.  Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.

Authors:  Sibylle Haid; Marc P Windisch; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

4.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.

Authors:  Nadja Müller; Susanne Michen; Stefanie Tietze; Katrin Töpfer; Alexander Schulte; Katrin Lamszus; Marc Schmitz; Gabriele Schackert; Ira Pastan; Achim Temme
Journal:  J Immunother       Date:  2015-06       Impact factor: 4.456

Review 5.  Biological treatment strategies for disc degeneration: potentials and shortcomings.

Authors:  Günther Paesold; Andreas G Nerlich; Norbert Boos
Journal:  Eur Spine J       Date:  2006-09-16       Impact factor: 3.134

6.  The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors:  George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.

Authors:  Julia Bitzegeio; Dorothea Bankwitz; Kathrin Hueging; Sibylle Haid; Christiane Brohm; Mirjam B Zeisel; Eva Herrmann; Marcus Iken; Michael Ott; Thomas F Baumert; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

8.  In vitro and in vivo gene delivery by recombinant baculoviruses.

Authors:  Hideki Tani; Chang Kwang Limn; Chan Choo Yap; Masayoshi Onishi; Masami Nozaki; Yoshitake Nishimune; Nobuo Okahashi; Yoshinori Kitagawa; Rie Watanabe; Rika Mochizuki; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles.

Authors:  Eike Steinmann; Christiane Brohm; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs.

Authors:  Jan Krönke; Ralf Kittler; Frank Buchholz; Marc P Windisch; Thomas Pietschmann; Ralf Bartenschlager; Michael Frese
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.